Enzo Biochem (NYSE:ENZ) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Enzo Biochem (NYSE:ENZ) in a report issued on Friday. The firm set a “hold” rating on the medical research company’s stock.

Enzo Biochem Stock Up 0.4 %

Enzo Biochem stock opened at $1.15 on Friday. Enzo Biochem has a 12 month low of $0.99 and a 12 month high of $1.50. The stock’s 50 day moving average is $1.13 and its 200-day moving average is $1.12.

Institutional Investors Weigh In On Enzo Biochem

A number of large investors have recently added to or reduced their stakes in ENZ. Renaissance Technologies LLC grew its position in Enzo Biochem by 2.6% during the second quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock worth $2,725,000 after buying an additional 64,417 shares in the last quarter. XTX Topco Ltd grew its position in Enzo Biochem by 94.5% during the second quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock worth $31,000 after buying an additional 13,735 shares in the last quarter. Finally, BBR Partners LLC acquired a new stake in Enzo Biochem during the third quarter worth approximately $112,000. Institutional investors and hedge funds own 36.90% of the company’s stock.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.